| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Guangxu Bai, Hao Wang, Na Cu. mTOR pathway mediates endoplasmic reticulum stress-induced CD4 Apoptosis : an international journal on programmed cell death. 2022-06-27. PMID:35759162. |
hence, in this study, a classical cecal ligation and puncture (clp) sepsis model was constructed by using the t cell-specific knockout mtor and tsc1 (tuberous sclerosis complex, the inhibitor of mtor signaling pathway) mice to explore the underlying signaling pathway and molecular mechanism of host immune imbalance caused by apoptosis in sepsis. |
2022-06-27 |
2023-08-14 |
mouse |
| Bartłomiej Pawlik, Urszula Smyczyńska, Szymon Grabia, Wojciech Fendler, Izabela Dróżdż, Katarzyna Bąbol-Pokora, Katarzyna Kotulska, Sergiusz Jóźwiak, Julita Borkowska, Wojciech Młynarski, Joanna Trelińsk. mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile. Journal of clinical medicine. vol 11. issue 12. 2022-06-24. PMID:35743464. |
mtor inhibitor treatment in patients with tuberous sclerosis complex is associated with specific changes in microrna serum profile. |
2022-06-24 |
2023-08-14 |
Not clear |
| Ines Serra, Ana Stravs, Catarina Osório, Maria Roa Oyaga, Martijn Schonewille, Christian Tudorache, Aleksandra Badur. Frontiers in molecular neuroscience. vol 15. 2022-06-01. PMID:35645731. |
tuberous sclerosis complex 1 (tsc1) is a tumor suppressor that promotes the inhibition of mechanistic target of rapamycin (mtor) pathway, and mutations in |
2022-06-01 |
2023-08-13 |
Not clear |
| Dominique F Leitner, Evgeny Kanshin, Manor Askenazi, Yik Siu, Daniel Friedman, Sasha Devore, Drew Jones, Beatrix Ueberheide, Thomas Wisniewski, Orrin Devinsk. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia. PloS one. vol 17. issue 5. 2022-05-19. PMID:35587487. |
tuberous sclerosis complex (tsc) and some focal cortical dysplasias (fcds) are associated with dysfunctional mtor signaling, resulting in increased cell growth and ribosomal s6 protein phosphorylation (phospho-s6). |
2022-05-19 |
2023-08-13 |
Not clear |
| Sandra Schrötter, Christopher J Yuskaitis, Michael R MacArthur, Sarah J Mitchell, Aaron M Hosios, Maria Osipovich, Margaret E Torrence, James R Mitchell, Gerta Hoxhaj, Mustafa Sahin, Brendan D Mannin. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth. Cell reports. vol 39. issue 7. 2022-05-18. PMID:35584673. |
the tuberous sclerosis complex (tsc) 1 and 2 proteins associate with tbc1d7 to form the tsc complex, which is an essential suppressor of mtor complex 1 (mtorc1), a ubiquitous driver of cell and tissue growth. |
2022-05-18 |
2023-08-13 |
mouse |
| Yasutaka Okita, Maiko Yoshimura, Yoshinori Katada, Yukihiko Saeki, Shiro Ohshim. A Mechanistic Target of Rapamycin (mTOR) Inhibitor, Everolimus Safely Ameliorated Lupus Nephritis in a Patient Complicated with Tuberous Sclerosis. Modern rheumatology case reports. 2022-05-05. PMID:35512453. |
a mechanistic target of rapamycin (mtor) inhibitor, everolimus safely ameliorated lupus nephritis in a patient complicated with tuberous sclerosis. |
2022-05-05 |
2023-08-13 |
Not clear |
| Yu-Ting Lin, Chia-Ling Yu, Yu-Kang Tu, Ching-Chi Ch. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis. Biomedicines. vol 10. issue 4. 2022-04-23. PMID:35453576. |
previous studies have suggested that the topical mechanistic target of rapamycin (mtor) inhibitors may be effective in treating facial angiofibromas in patients with tuberous sclerosis complex (tsc). |
2022-04-23 |
2023-08-13 |
Not clear |
| Cong Luo, Wen-Rui Ye, Wei Shi, Ping Yin, Chen Chen, Yun-Bo He, Min-Feng Chen, Xiong-Bin Zu, Yi Ca. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet journal of rare diseases. vol 17. issue 1. 2022-03-05. PMID:35246210. |
perfect match: mtor inhibitors and tuberous sclerosis complex. |
2022-03-05 |
2023-08-13 |
human |
| Wenda Wang, Zhan Wang, Yang Zhao, Xu Wang, Hanzhong Li, Yushi Zhan. Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC-AML patients with treatment of mTOR inhibitors. Journal of clinical pharmacy and therapeutics. 2022-03-01. PMID:35229896. |
patients with tuberous sclerosis complex (tsc) demonstrate disrupted lipid homeostasis before and during treatment with mammalian target of rapamycin (mtor) inhibitor. |
2022-03-01 |
2023-08-13 |
Not clear |
| Lena H Nguyen, Steven C Leiser, Dekun Song, Daniela Brunner, Steven L Roberds, Michael Wong, Angelique Borde. Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy research. vol 181. 2022-02-26. PMID:35219048. |
tuberous sclerosis complex (tsc) is a monogenic disorder characterized by hyperactivation of the mtor signaling pathway and developmental brain malformations leading to intractable epilepsy. |
2022-02-26 |
2023-08-13 |
mouse |
| Jennifer M Gibson, Cleone P Howland, Chongyu Ren, Cyrena Howland, Alexandra Vernino, Peter T Tsa. A critical period for development of cerebellar-mediated autism-relevant social behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2022-02-22. PMID:35190469. |
in this study, we identify a critical period for the development of asd-relevant behaviors in a cerebellar male mouse model of tuberous sclerosis complex (tsc), by using the mechanistic target of rapamycin (mtor) inhibitor, rapamycin, to pharmacologically inhibit dysregulated downstream signaling. |
2022-02-22 |
2023-08-13 |
mouse |
| Andrew R Tee, Brendan D Manning, Philippe P Roux, Lewis C Cantley, John Bleni. Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb. Current biology : CB. vol 32. issue 3. 2022-02-08. PMID:35134350. |
tuberous sclerosis complex gene products, tuberin and hamartin, control mtor signaling by acting as a gtpase-activating protein complex toward rheb. |
2022-02-08 |
2023-08-13 |
Not clear |
| Pedram Argani, Rohit Mehr. Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2022-01-20. PMID:35046523. |
renal cell carcinoma associated with tuberous sclerosis complex (tsc)/mammalian target of rapamycin (mtor) genetic alterations. |
2022-01-20 |
2023-08-13 |
Not clear |
| Victoria-Elisabeth Gruber, Mark J Luinenburg, Katrin Colleselli, Verena Endmayr, Jasper J Anink, Till S Zimmer, Floor Jansen, Peter Gosselaar, Roland Coras, Theresa Scholl, Ingmar Blumcke, José Pimentel, Johannes A Hainfellner, Romana Höftberger, Karl Rössler, Martha Feucht, Jackelien van Scheppingen, Eleonora Aronica, Angelika Mühlebne. Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions. Epilepsia. 2021-12-14. PMID:34904712. |
increasing evidence supports the contribution of inflammatory mechanisms to the neurological manifestations of epileptogenic developmental pathologies linked to mammalian target of rapamycin (mtor) pathway dysregulation (mtoropathies), such as tuberous sclerosis complex (tsc) and focal cortical dysplasia (fcd). |
2021-12-14 |
2023-08-13 |
Not clear |
| Saber Tadros, Aleksei Kondrashov, Sriya Namagiri, Ashis Chowdhury, Yeshavanth Kumar Banasavadi-Siddegowda, Abhik Ray-Chaudhur. Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review. Neurosurgery. vol 89. issue 3. 2021-11-25. PMID:33693933. |
understanding the signaling pathway alteration of mammalian target of rapamycin (mtor) in tuberous sclerosis helped introducing mtor inhibitors as a prophylactic treatment in these patients. |
2021-11-25 |
2023-08-13 |
Not clear |
| Felipe I Chodraui, Camila Araújo B Garcia, Niele D Mendes, Marcelo V Santos, Pâmela S Beggiora, Stephanya C Silva, Thiago L Teixeira, Luiza da Silva Lopes, Fabiano P Saggioro, Luciano Neder, Hélio R Machad. Phosphorylation of S6 Protein as a Potential Biomarker in Surgically Treated Refractory Epilepsy. Developmental neuroscience. vol 42. issue 5-6. 2021-11-16. PMID:33706310. |
the tuberous sclerosis complex (tsc), focal cortical dysplasia iib (fcd iib), and hemimegalencephaly (hme) exhibit similar molecular features that are dependent on the hyperactivation of the mtor pathway. |
2021-11-16 |
2023-08-13 |
Not clear |
| Elhusseiny Mohamed Mahmoud Abdelwahab, Judit Bovari-Biri, Gabor Smuk, Tunde Harko, Janos Fillinger, Judit Moldvay, Vera P Krymskaya, Judit E Pongrac. Normalization of Enzyme Expression and Activity Regulating Vitamin A Metabolism Increases RAR-Beta Expression and Reduces Cellular Migration and Proliferation in Diseases Caused by Tuberous Sclerosis Gene Mutations. Frontiers in oncology. vol 11. 2021-11-12. PMID:34178631. |
mutation in a tuberous sclerosis gene (tsc1 or 2) leads to continuous activation of the mammalian target of rapamycin (mtor). |
2021-11-12 |
2023-08-13 |
Not clear |
| Elin Vinsland, Pranetha Baskaran, Simeon R Mihaylov, Carl Hobbs, Hannah Wood, Ihssane Bouybayoune, Kriti Shah, Corinne Houart, Andrew R Tee, Jernej Murn, Cathy Fernandes, Joseph M Batema. The zinc finger/RING domain protein Unkempt regulates cognitive flexibility. Scientific reports. vol 11. issue 1. 2021-11-12. PMID:34381067. |
activation of mtor signaling causes diseases with severe neurological manifestations, such as tuberous sclerosis complex and focal cortical dysplasia. |
2021-11-12 |
2023-08-13 |
mouse |
| Michael Won. mTOR as a potential treatment target for epilepsy. Future neurology. vol 7. issue 5. 2021-11-10. PMID:23620711. |
mtor inhibitors can suppress seizures and prevent epilepsy in animal models of certain genetic epilepsies, such as tuberous sclerosis complex. |
2021-11-10 |
2023-08-12 |
Not clear |
| Michael Won. mTOR as a potential treatment target for epilepsy. Future neurology. vol 7. issue 5. 2021-11-10. PMID:23620711. |
some clinical data suggest that mtor inhibitors decrease seizures in tuberous sclerosis complex patients, but controlled trials are lacking and no clinical data on potential anti-epileptogenic actions exist. |
2021-11-10 |
2023-08-12 |
Not clear |